Search Results

Gryphon Investors (“Gryphon”), a leading middle-market private equity firm, today announced that it has acquired Vetnique Labs (“Vetnique” or the “Company”).

- Gryphon Investors (“Gryphon”), a leading middle-market private equity firm, announced today that it has signed a definitive agreement to sell its portfolio company CORA Health Holdings Corp. (“CORA,” “CORA Physical Therapy,” or “the Company”) to an affiliate of H.I.G. Capital. Gryphon originally invested in the Company in July 2016 .

Novo Nordisk executives set a high bar for itself when it projected CagriSema could achieve 25% weight loss. When the GLP-1 combo didn’t hit that mark, investors reeled.

While Amgen’s third-quarter financial results on Wednesday were “somewhat uneventful,” investors continue to be focused on the highly anticipated MariTide Phase II results slated for late 2024, according to BMO Capital Markets analyst Evan Seigerman.

Owl Therapeutics, a wholly-owned subsidiary of Gryphon Bio, today announced a global licensing and collaboration agreement with Abliva AB of Lund, Sweden, to advance Abliva’s NeuroSTAT® (OWL-1410) for the prevention and treatment of moderate to severe traumatic brain injury (TBI).

The approval makes Pfizer’s Hympavzi the first once-weekly subcutaneous prophylactic injection for hemophilia B in the U.S., according to the company, which is currently embroiled in a row with activist investor Starboard Value.

CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer reported that third-quarter revenue and adjusted profit beat the analysts’ consensus.